Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, VEN

Inceptor Bio Launches Next-Generation CAR-T, CAR-M, and NK/NKT Platform Focused on Advancing Cell and Gene Therapies to Cure Difficult-To-Treat Cancers


RALEIGH, N.C., June 14, 2021 /PRNewswire/ -- Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotech, announced today that it is developing multiple next-generation cell and gene therapy platforms to cure difficult-to-treat cancers. Inceptor Bio will create a portfolio of companies focused on specific platform technologies, supported by its Advanced Manufacturing Platform (AMP+) and other shared infrastructure.

Inceptor Bio was established to pursue a diversified portfolio of cell therapy platforms across multiple cell types, including CAR-T, CAR-M, and CAR-NK/NKT, with novel mechanisms that enhance immune cell performance within the tumor microenvironment. The company collaborates with leading scientists at premier academic institutions to license groundbreaking cell and gene technologies.

Inceptor Bio's Advanced Manufacturing Platform (AMP+) is a shared cell and gene therapy manufacturing facility that is central to executing the company's differentiated strategy. AMP+ is a fit-for-purpose, capital efficient, and scalable manufacturing facility that provides expertise and capacity for critical viral vector and cell therapy operations serving all portfolio companies.

Inceptor Bio is led by a management team, Board of Directors, and Scientific Advisory Board that represent an unparalleled breadth of experience in the cell and gene therapy sector, with a track record of execution and successful development of pioneering medicines at industry leaders such as Precision BioSciences, Juno Therapeutics, Brammer Bio, Catalent, and Roche.

Shailesh Maingi, Founder, Chairman and CEO of Inceptor Bio, said, "We started Inceptor Bio with a simple purpose ? to provide better options for patients with difficult-to-treat cancers. In solid tumors, where there are limited treatment options, patient outcomes remain poor, and cures are elusive. But there is hope with advances in cell and gene therapy. Our mission is consequently to advance multiple next-generation CAR-T, CAR-M and CAR-NK/NKT platforms in collaboration with leading universities to cure these cancers.

Maingi continued, "We are privileged to have an outstanding team of pioneers in cell and gene therapy executing our vision. Our operations strategy starts with AMP+, our Advanced Manufacturing Platform for viral vector and cell therapy operations, which allows us to maintain internal control of development and manufacturing. We are delighted to partner with leading academic collaborators in our shared mission to end cancer."

The seed round was led by the Kineticos Disruptor Fund. Frank Lis, Kineticos Ventures President and CEO, said, "We are delighted to lead the seed round for Inceptor Bio, which has an exceptional cell and gene therapy team, dedicated manufacturing in AMP+, and a unique collaborative model with top research universities. The products being developed by Inceptor Bio will have a profound impact on the lives of many cancer patients."

Inceptor Bio has also launched a new website at www.inceptor.bio to provide information on the company's vision and activities.

About Inceptor Bio
Founded in 2020, Inceptor Bio is biotechnology company developing multiple next-generation cell and gene therapy platforms to deliver cures for underserved and difficult-to-treat cancers. By partnering with universities, medical centers, and industry leaders, Inceptor Bio advances cell and gene therapy programs from discovery-phase technologies into Phase I and II clinical assets. An experienced management team, Scientific Advisory Board, and other Directors and strategic advisors offer industry-leading expertise to partnerships. Inceptor Bio is investing in an Advanced Manufacturing Platform (AMP+) to provide fit-for-purpose, capital efficient, scalable shared infrastructure to support advancement of a diversified portfolio of cell therapy platforms across multiple cell types, including CAR-T, CAR-M, and CAR-NK/NKT. Additional information about Inceptor Bio is available at www.inceptor.bio.

Inceptor Bio media contact:
Wei Gao
That's Nice LLC
T: +1 212 366 4455
E: [email protected]

SOURCE Inceptor Bio


These press releases may also interest you

at 14:25
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and...

at 14:20
Mishe (say "mish-e"), an innovator in direct healthcare, announces the launch of Downstate's Transparent Access Plan, making SUNY Downstate Health Sciences University the first hospital system in the US to offer transparent upfront pricing for its...

at 14:19
Sharp Imaging and Information Company of America (Sharp), a division of Sharp Electronics Corporation (SEC), today announced that industry veteran, Dino Pagliarello, has joined Sharp as the new Vice President of Product Management and Production...

at 14:15
The "Poland Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2024 Update" report has been added to ResearchAndMarkets.com's offering. The Polish gift card market demonstrates robust growth trends, with an...

at 14:15
Building on its commitment to leveraging advanced technology for enhanced learning experiences, Blueprint Prep is proud to announce a significant expansion in the capabilities of its AI-powered tutor, Blue. Initially launched to provide personalized...

at 14:00
Amsive, a data-led performance marketing agency, has again attained Premier Partner status within the Google Partners program for 2024. This milestone marks a moment of great pride as the agency celebrates our recognition in the program for more than...



News published on and distributed by: